Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

Cai, now 46, was diagnosed with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, back in 2019. As one of the most ...

Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1 clinical trial of AMX0114, ...

Ancient viral DNA embedded in the human genome has been linked to the genetic risks of certain neurodegenerative diseases, ...

Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease ...

Background A growing evidence base supports the use of autologous haematopoietic stem cell transplantation (aHSCT) for treatment of relapsing-remitting multiple sclerosis (RRMS ... forms of MS where ...

Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].

For the primary analysis, 186 participants who were randomized to receive DNL343 treatment were compared to 139 participants randomized to receive placebo in this regimen (n=63) or shared from a ...

“Better treatment options for individuals with ALS are critically ... and will further evaluate the data before determining next steps.” About ALS Amyotrophic lateral sclerosis (ALS) is the most ...